[Multimodal therapy of prostate cancer - 2 case reports].
The importance of the carcinoma of the prostate is still increasing. It is important to have options such as multimodal therapy. In this article two selected case reports are presented. Treatment options such as surgery, hormonal and irradiation therapy as well as chemotherapy will be discussed. Each patient suffering from carcinoma of prostate should receive individual best therapy.
Lamche
Michael
M
Abteilung für Urologie und Andrologie des Krankenhauses der Barmherzigen Brüder Wien, Wien, Austria. michael.lamche@bbwien.at
Bauer
Wilhelm A
WA
Schramek
Paul
P
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D003131:Combined Modality Therapy; D006801:Humans; D010535:Laparoscopy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D012086:Reoperation; D016879:Salvage Therapy; D020728:Transurethral Resection of Prostate
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen